NAFLD Research Center - Altman Clinical and Translational Research Institute
Welcome,         Profile    Billing    Logout  
 16 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Loomba, Rohit
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RAMIC, NCT04366050: Ramipril for the Treatment of COVID-19

Completed
2
160
US
Ramipril 2.5 MG Oral Capsule, Ramipril, Placebo oral capsule, Placebo
University of California, San Diego, Pfizer
COVID-19
05/21
05/21
ELPISII, NCT04925024: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Active, not recruiting
2
40
US
Lomecel-B medicinal signaling cells
Longeveron Inc., National Heart, Lung, and Blood Institute (NHLBI), Ann & Robert H Lurie Children's Hospital of Chicago, The University of Texas Health Science Center, Houston
Hypoplastic Left Heart Syndrome
06/26
08/26
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
NCT04483947: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Completed
1
74
US
AZD2693, Placebo
AstraZeneca, Parexel
Non-alcoholic Steatohepatitis (NASH)
12/23
12/23
NCT02124577: Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

Recruiting
N/A
50
US
University of California, San Diego, KineMed
Non-alcoholic Fatty Liver Disease
05/21
05/21
Smith
BROOKLYN, NCT05425745 / 2021-005064-22: Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Completed
3
354
Europe, Canada, US, RoW
Obicetrapib, CETP-inhibitor, Placebo
NewAmsterdam Pharma
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
05/24
05/24
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NalPORS, NCT05072249: European Cohort Study of the Effectiveness of Take Home Naloxone

Recruiting
N/A
6000
Europe
Naloxone, Prenoxad, Nyxoid, Ventizolve
King's College London, Mundipharma Research Limited
Opioid Overdose
12/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Loomba, Rohit
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
RAMIC, NCT04366050: Ramipril for the Treatment of COVID-19

Completed
2
160
US
Ramipril 2.5 MG Oral Capsule, Ramipril, Placebo oral capsule, Placebo
University of California, San Diego, Pfizer
COVID-19
05/21
05/21
ELPISII, NCT04925024: Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Active, not recruiting
2
40
US
Lomecel-B medicinal signaling cells
Longeveron Inc., National Heart, Lung, and Blood Institute (NHLBI), Ann & Robert H Lurie Children's Hospital of Chicago, The University of Texas Health Science Center, Houston
Hypoplastic Left Heart Syndrome
06/26
08/26
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
04/27
NCT04483947: A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Completed
1
74
US
AZD2693, Placebo
AstraZeneca, Parexel
Non-alcoholic Steatohepatitis (NASH)
12/23
12/23
NCT02124577: Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

Recruiting
N/A
50
US
University of California, San Diego, KineMed
Non-alcoholic Fatty Liver Disease
05/21
05/21
Smith
BROOKLYN, NCT05425745 / 2021-005064-22: Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Completed
3
354
Europe, Canada, US, RoW
Obicetrapib, CETP-inhibitor, Placebo
NewAmsterdam Pharma
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
05/24
05/24
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects

Recruiting
2
240
US, RoW
HM15211, efocipegtrutide, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
NalPORS, NCT05072249: European Cohort Study of the Effectiveness of Take Home Naloxone

Recruiting
N/A
6000
Europe
Naloxone, Prenoxad, Nyxoid, Ventizolve
King's College London, Mundipharma Research Limited
Opioid Overdose
12/23
12/23

Download Options